Short Interest Update on AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals (AMAG) : The short interest in AMAG Pharmaceuticals (AMAG) has changed with an increase of 265,117 shares and the open interest is 3.7%. From 7,187,922 short positions on Jul 29, 2016, the shorts increased to 7,453,039 shares by August 15, 2016. There are 5 more days left for the expiry and the daily trading volume of the stock is 1,432,482 shares. The total interest of shorts is 21.9% of the shares available to the public. The short interest information was released on Wednesday Aug 24th after the market close.

AMAG Pharmaceuticals (NASDAQ:AMAG): The stock opened at $26.44 on Wednesday but the bulls could not build on the opening and the stock topped out at $26.95 for the day. The stock traded down to $24.55 during the day, due to lack of any buying support eventually closed down at $24.85 with a loss of -5.62% for the day. The stock had closed at $26.33 on the previous day. The total traded volume was 1,138,136 shares.


In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Amag Pharmaceuticals Inc., Fallon John A., had purchased 3,230 shares in a transaction dated on November 10, 2015. The transaction was executed at $31.2 per share with total amount equaling $100,776.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.